Sofinnova BioEquities, LP
These Form D notices describe private placements reported to the SEC. Read Form D/A amendments alongside the original disclosures.
through May 8, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Differences between reported disclosures
Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.
| Field | May 9, 2025 · D/A | May 8, 2026 · D/A | Later minus earlier |
|---|---|---|---|
| Reported offering amount | — | — | — |
| Reported amount sold | $363,726,521 | $376,921,569 | $13,195,048 |
| Reported investor count | — | — | — |
| Reported minimum investment | $0 | $0 | $0 |
Earlier SEC source: 0000919574-25-002791 · Later SEC source: 0000919574-26-002769
Choose filings to compare · Research this issuer step by step
Latest available filing snapshot: how to read these fields
- Reported offering amount
- —
- Reported exemptions
- Rule 506(b), Investment Company Act Section 3(c), Investment Company Act Section 3(c)(7)
- Reported amount sold
- $376,921,569
This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.
Filings by year
- 20251 filing
- 20261 filing
Submission counts, including amendments; not dollars raised or distinct funding rounds.
Related person name and locality match
Matches in stored disclosures are research leads. They do not establish common ownership or confirm identity.
- Sofinnova BioEquities Enhanced Master Fund, LP · CIK 1949475
- Sofinnova BioEquities Enhanced Offshore Fund Ltd. · CIK 1949442
Form D filings (2)
-
0000919574-26-002769D/A · May 8, 2026 · Pooled Investment FundSold: $376,921,569
Compared with 0000919574-25-002791:
- Reported amount sold: $363,726,521 → $376,921,569
-
0000919574-25-002791D/A · May 9, 2025 · Pooled Investment FundSold: $363,726,521